Genotypic Analysis of Drug-Resistant HIV Cost-Effective
WESTPORT, Conn-Genotypic analysis of drug-resistant HIV strains appears to be cost-effective.
A new study conducted by Milton C. Weinstein, MD, from the Harvard School of Public Health, used an HIV simulation model to incorporate data from several HIV-related trials to analyze the cost-effectiveness of genotypic resistance testing. HIV-infected subjects with baseline CD4 counts of 250 cells per microliter were the target group.
Researchers found that testing following antiretroviral failure increased life expectancy by 3 months and cost $17,900 per quality-adjusted-life-year (QALY) gained. The figure for primary resistance testing was $22,300 with 20% prevalence of primary resistance, but increased to $69,000 when prevalence was assumed to be only 4%.
The cost per QALY gained never exceeded $25,000 when effectiveness, multiple cost factors, quality-of-life weights, and discount rates were varied.
Information from www.hivandhepatitis.com
“A Coup Against Science”: Health Groups Decry Kennedy’s Firing of National Vaccine Advisory Panel
June 12th 2025Health leaders are outraged after HHS Secretary Robert F. Kennedy Jr. abruptly fired all 17 members of the CDC’s vaccine advisory panel, calling it a political purge that threatens public trust and vaccine safety.
AHE Exchange Summit 2025 Brings EVS and Infection Prevention Experts Together in Columbus, Ohio
June 9th 2025The Association for the Health Care Environment (AHE) is set to host its largest event of the year—Exchange Summit 2025—from June 8 to 11 in Columbus, Ohio. With over 600 environmental services (EVS) professionals expected to attend, this year’s conference focuses heavily on infection prevention, interdepartmental collaboration, and education that empowers frontline health care support leaders to improve patient safety and operational efficiency.
